1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

'Cures' vs Funding: FDA Appropriations Bill Is Latest Battleground

 
• By Derrick Gingery

The FDA policy reform debate just got more contentious.

If the House appropriations bill for FDA is enacted as drafted, the agency will be facing a series of unfunded and underfunded mandates, reflecting a change in the debate on regulatory reform.

Within the House fiscal year 2017 appropriations bill for the agency are provisions enacting portions of the House 21st Century Cures package, including those allowing an expansion

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.

More from North America